Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kochanek

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Gene Therapy|July 23, 2004
CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscleZ Jiang, G Schiedner, S C Gilchrist, et al.
Human Gene Therapy|May 8, 2001
Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectorsC E Thomas, G Schiedner, S Kochanek, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2000
Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseasesC E Thomas, G Schiedner, S Kochanek, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 1999
Adenovirus-mediated regulable target gene expression in vivoM M Burcin, G Schiedner, S Kochanek, et al.
Histochemistry and Cell Biology|August 2, 2001
Comparison of long-term transgene expression after non-viral and adenoviral gene transfer into primary articular chondrocytesR Dinser, F Kreppel, F Zaucke, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 1996
A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidaseS Kochanek, P R Clemens, K Mitani, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 1997
Persistence in muscle of an adenoviral vector that lacks all viral genesH H Chen, L M Mack, R Kelly, et al.
Cell Transplantation|February 7, 2004
Neural precursor cells as carriers for a gene therapeutical approach in tumor therapyS Arnhold, M Hilgers, D Lenartz, et al.
Human Gene Therapy|September 19, 2001
Targeting of high-capacity adenoviral vectorsV Biermann, C Volpers, S Hussmann, et al.
FEBS Letters|August 1, 1990
Eukaryotic DNA methylation: facts and problemsW Doerfler, M Toth, S Kochanek, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Gene Therapy|July 23, 2004
CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscleZ Jiang, G Schiedner, S C Gilchrist, et al.
Human Gene Therapy|May 8, 2001
Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectorsC E Thomas, G Schiedner, S Kochanek, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2000
Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseasesC E Thomas, G Schiedner, S Kochanek, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 1999
Adenovirus-mediated regulable target gene expression in vivoM M Burcin, G Schiedner, S Kochanek, et al.
Histochemistry and Cell Biology|August 2, 2001
Comparison of long-term transgene expression after non-viral and adenoviral gene transfer into primary articular chondrocytesR Dinser, F Kreppel, F Zaucke, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 1996
A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidaseS Kochanek, P R Clemens, K Mitani, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 1997
Persistence in muscle of an adenoviral vector that lacks all viral genesH H Chen, L M Mack, R Kelly, et al.
Cell Transplantation|February 7, 2004
Neural precursor cells as carriers for a gene therapeutical approach in tumor therapyS Arnhold, M Hilgers, D Lenartz, et al.
Human Gene Therapy|September 19, 2001
Targeting of high-capacity adenoviral vectorsV Biermann, C Volpers, S Hussmann, et al.
FEBS Letters|August 1, 1990
Eukaryotic DNA methylation: facts and problemsW Doerfler, M Toth, S Kochanek, et al.
Pageof 6